In Situ Hybridization Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By End User, By Region & Competition, 2021-2031F

The Global In Situ Hybridization (ISH) Market is set for substantial growth, projected to expand from USD 1.98 billion in 2025 to USD 3.11 billion by 2031, demonstrating a 7.82% compound annual growth rate. This molecular cytogenetic technique, crucial for localizing specific DNA or RNA sequences within tissue sections using labeled probes, is primarily propelled by the escalating global incidence of malignancies and genetic disorders, which demand precise companion diagnostics. For instance, the American Cancer Society estimated 2,041,910 new cancer cases in the United States in 2025, while Cancer Research UK reported that approximately 3.5 million individuals were living with cancer in the UK in June 2025, underscoring the intensified need for advanced molecular tools. This rising disease burden drives diagnostic laboratories to scale operations, significantly influencing industry revenue, as exemplified by Roche's Diagnostics Division generating CHF 14.3 billion in annual sales in January 2025. Furthermore, surging investments in pharmaceutical and biotechnology research and development, such as Novartis's USD 10 billion R&D investment in 2024, are accelerating the adoption of high-throughput ISH systems to identify novel therapeutic targets and validate treatment efficacy through spatial biology techniques. However, the market faces significant hurdles, notably the considerable capital investment required for automated imaging systems and reagents, along with a shortage of skilled pathologists.

These financial and technical constraints significantly impede market expansion, as the high cost of advanced diagnostic infrastructure and recurring reagent expenses create formidable entry barriers, particularly for smaller laboratories and those in developing regions. This economic challenge is compounded by an acute global shortage of skilled pathologists and laboratory scientists proficient in interpreting complex molecular assays, with approximately 78% of surveyed pathologists reporting insufficient staffing levels to meet growing diagnostic workloads in 2025. Despite these challenges, the market is undergoing transformative shifts driven by key trends, including the convergence of in situ hybridization with spatial biology and transcriptomics, which enables unprecedented cellular resolution for visualizing gene expression and understanding disease mechanisms, as evidenced by Bio-Techne Corporation's Diagnostics and Spatial Biology segment reporting 12% organic revenue growth in Q2 Fiscal 2025. Simultaneously, the integration of artificial intelligence and digital pathology is revolutionizing ISH image analysis by automating the interpretation of high-plex assays, overcoming manual scoring subjectivity, and enhancing diagnostic precision, a trend supported by significant investments like Proscia securing USD 50 million in Series C funding to advance its AI-powered pathology platform.

Market Driver

The rising global prevalence of cancer and genetic disorders serves as a primary engine for the In Situ Hybridization (ISH) Market, creating an intensified demand for precise molecular cytogenetic tools to identify chromosomal abnormalities and validate biomarkers within tissue samples. This escalating disease burden is evident in statistics such as the nearly 3.5 million individuals living with cancer in the UK in June 2025, as reported by Cancer Research UK, a significant increase from 3 million in 2020. Consequently, diagnostic laboratories are expanding their operations to accommodate higher testing volumes, directly boosting the revenue streams of major industry players, demonstrated by Roche's Diagnostics Division's CHF 14.3 billion in annual sales in January 2025. Additionally, substantial investments in pharmaceutical and biotechnology research and development further propel the market by necessitating robust tools for drug discovery and development. Pharmaceutical companies are increasingly dedicating capital to identify novel therapeutic targets and validate treatment efficacy through spatial biology techniques, with an example being Novartis's USD 10 billion investment in R&D in 2024. This capital influx supports the adoption of high-throughput ISH systems, empowering researchers to visualize gene expression with spatial context and thereby accelerating the translation of genomic insights into clinical therapies.

Market Challenge

The growth of the Global In Situ Hybridization Market is substantially hampered by two key factors: the high capital expenditure required for advanced diagnostic infrastructure and a critical scarcity of specialized professionals. The significant cost associated with acquiring automated imaging systems and the ongoing expense of specialized reagents establish a formidable entry barrier for numerous healthcare institutions. This financial exclusivity often restricts the adoption of these advanced molecular techniques to well-funded academic and reference laboratories, limiting their broader penetration into decentralized healthcare settings and hindering the market from reaching its full potential. Compounding this economic hurdle is a severe global shortage of skilled pathologists and laboratory scientists adept at interpreting complex molecular assays. The intricate nature of in situ hybridization results demands a high level of technical expertise, yet the workforce capable of these duties is insufficient relative to the escalating clinical demand. For instance, in 2025, approximately 78% of surveyed pathologists reported that current staffing levels were inadequate to manage the growing diagnostic workload. This workforce bottleneck not only prolongs test turnaround times but also constrains laboratories' capacity to scale operations, directly impeding the overall expansion of the market, despite the increasing prevalence of diseases that necessitate these diagnostics.

Market Trends

The convergence of in situ hybridization with spatial biology and transcriptomics signifies a transformative evolution within the market, empowering researchers to visualize gene expression with unparalleled cellular resolution. This integration is crucial for precisely mapping complex tissue microenvironments, which is increasingly vital for gaining a deeper understanding of disease mechanisms and developing effective targeted therapies. The growing adoption of these combined workflows is reflected in the financial performance of leading industry innovators, such as Bio-Techne Corporation, whose Diagnostics and Spatial Biology segment reported a 12% organic revenue growth in the second quarter of Fiscal 2025, highlighting the rapid uptake of advanced spatial profiling tools leveraging hybridization techniques. Concurrently, the incorporation of artificial intelligence (AI) and digital pathology is reshaping in situ hybridization image analysis by automating the interpretation of complex, high-plex assays. Laboratories are progressively implementing AI-driven software solutions to overcome the subjectivity inherent in manual scoring and to effectively manage the vast datasets generated by contemporary multiplexing platforms, thereby significantly enhancing diagnostic precision. This trend is further propelled by substantial targeted capital inflows aimed at expanding digital infrastructure and computational capabilities within the sector, exemplified by Proscia securing USD 50 million in Series C funding in March 2025 to advance its AI-powered pathology platform, which directly facilitates the broader integration of computational analysis into routine tissue-based diagnostic workflows.

Key Market Players

• Thermo Fisher Scientific, Inc.
• Abbott Laboratories Inc.
• PerkinElmer, Inc.
• Bio View Ltd.
• Agilent Technologies, Inc.
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Biotechne Corporation
• F. Hoffmann Roche AG
• Biocare Medical LLC

Report Scope

In this report, the Global In Situ Hybridization Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

In Situ Hybridization Market, By Product

• Instruments
• Consumables & Accessories
• Software
• Services

In Situ Hybridization Market, By Technology

• Fluorescent In Situ Hybridization
• Chromogenic In Situ Hybridization

In Situ Hybridization Market, By Application

• Cancer
• Cytogenetics
• Infectious Diseases
• Neuroscience
• Immunology
• Others

In Situ Hybridization Market, By End User

• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Others

In Situ Hybridization Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global In Situ Hybridization Market.

Available Customizations:

Global In Situ Hybridization Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).